Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to 16966.13%.

  • Roivant Sciences' EBITDA Margin fell 139235400.0% to 16966.13% in Q4 2025 from the same period last year, while for Dec 2025 it was 20987.61%, marking a year-over-year decrease of 415114000.0%. This contributed to the annual value of 3453.32% for FY2025, which is 172002500.0% down from last year.
  • As of Q4 2025, Roivant Sciences' EBITDA Margin stood at 16966.13%, which was down 139235400.0% from 19492.87% recorded in Q3 2025.
  • Roivant Sciences' 5-year EBITDA Margin high stood at 32948.56% for Q4 2023, and its period low was 19492.87% during Q3 2025.
  • Over the past 5 years, Roivant Sciences' median EBITDA Margin value was 3042.59% (recorded in 2024), while the average stood at 3642.27%.
  • Per our database at Business Quant, Roivant Sciences' EBITDA Margin surged by 351657600bps in 2023 and then tumbled by -359911500bps in 2024.
  • Over the past 5 years, Roivant Sciences' EBITDA Margin (Quarter) stood at 1010.73% in 2021, then tumbled by -119bps to 2217.2% in 2022, then soared by 1586bps to 32948.56% in 2023, then crashed by -109bps to 3042.59% in 2024, then crashed by -458bps to 16966.13% in 2025.
  • Its EBITDA Margin stands at 16966.13% for Q4 2025, versus 19492.87% for Q3 2025 and 13130.05% for Q2 2025.